Atara Biotherapeutics (ATRA) FCF Margin (2021 - 2026)
Atara Biotherapeutics' (ATRA) quarterly FCF Margin came in at 529.84% in Q2 2026, down 48820.0% on a YoY basis from N/an in Q2 2025, and up 11.03% quarter-over-quarter from 595.54% in Q1 2026.
Powered by 
Analysis
Atara Biotherapeutics (ATRA) FCF Margin (2021 - 2026) Analysis & Trends
Atara Biotherapeutics (ATRA) has reported FCF Margin for 6 consecutive years, with 529.84% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, FCF Margin fell 48820.0% year-over-year to 529.84%; the trailing twelve-month figure through Jun 2026 stood at 353.49% (down 31956.0% YoY), and the FY2025 full-year result was 42.18%, up 1131.0% from the prior year.
- FCF Margin improved to 529.84% in Q2 2026 per ATRA's latest filing, from 595.54% in the prior quarter.
- Across five years, FCF Margin topped out at 9.93% in Q3 2024 and bottomed at 22950.4% in Q4 2022.
- Historically, FCF Margin has averaged 2229.72% across 5 years, with a median of 443.51% in 2025.
- The sharpest annual moves came in 2022 and 2023: FCF Margin slumped 2246372 bps in 2022, then soared 2176390 bps in 2023.
- Over 5 years, FCF Margin stood at 22950.4% in 2022, then surged by 95 bps to 1186.5% in 2023, then surged by 94 bps to 74.99% in 2024, then sank by 376 bps to 357.18% in 2025, then slumped by 48 bps to 529.84% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 529.84%, 595.54%, and 357.18% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.21 Bn | 9.37 Bn | 112.79 Mn | 59.74% |
| 2 | CRISPR Therapeutics AG | 5.04 Bn | 5.04 Bn | - | -826.50% |
| 3 | Iovance Biotherapeutics | 3.65 Bn | 3.36 Bn | 55.72 Mn | -66.71% |
| 4 | Legend Biotech | 3.54 Bn | 2.57 Bn | 251.50 Mn | -3.46% |
| 5 | uniQure | 2.95 Bn | 2.95 Bn | 5.49 Mn | -497.31% |
| 6 | Beam Therapeutics | 2.55 Bn | 2.55 Bn | - | -13,981.63% |
| 7 | Precigen | 2.39 Bn | 2.39 Bn | 52.17 Mn | -33.11% |
| 8 | Sarepta Therapeutics | 2.16 Bn | 1.37 Bn | 251.87 Mn | 48.98% |
| 9 | Vericel | 1.93 Bn | 1.77 Bn | 56.40 Mn | 18.67% |
| 10 | Atara Biotherapeutics | 148.00 Mn | 131.45 Mn | 439,000.00 | -529.84% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -529.84% |
| Mar 31, 2026 | -595.54% |
| Dec 31, 2025 | -357.18% |
| Sep 30, 2025 | -283.43% |
| Jun 30, 2025 | -41.64% |
| Mar 31, 2025 | -28.67% |
| Dec 31, 2024 | -74.99% |
| Sep 30, 2024 | -9.93% |
| Jun 30, 2024 | -37.27% |
| Mar 31, 2024 | -108.71% |
| Dec 31, 2023 | -1,186.50% |
| Sep 30, 2023 | -2,414.73% |
| Jun 30, 2023 | -5,568.97% |
| Mar 31, 2023 | -3,167.05% |
| Dec 31, 2022 | -22,950.40% |
| Sep 30, 2022 | -1,461.96% |
| Jun 30, 2022 | -126.76% |
| Mar 31, 2022 | -1,191.33% |
| Dec 31, 2021 | -486.69% |
| Sep 30, 2021 | -1,170.09% |